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The clinical trial directive 2001/20/EC is out for public
consultation. This session will draw the attention of the
challenges faced by Small and Medium Enterprises
(SME) companies when developing new products for
the rare diseases that affect a very limited number of
patients and discuss possible options to overcome the
challenges.
Indeed, with only a few patients in each country, clini-
cal trials need to be conducted in many countries in
order to enrol the number of patients required to
demonstrate benefit/risk. The management of these clin-
ical trials is associated with several issues that slow
down the overall process of drug development: adminis-
trative hurdles associated with non harmonised regula-
tory authorisation process as well as cost pressure
linked to the need to outsource local activities to several
consultants to prepare and manage submission to health
authorities and ethic committees.
Today, Europe must streamline its system and all sta-
keholders should raise their voice to propose specific
approaches in order to facilitate the development of new
drugs for orphan drugs in a timely manner.
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